In today's clinical practice, there is no appropriate "one size fits all" treatment approach for COPD. But while this progressive trend toward personalized medicine standards helps optimize COPD care for each patient, the cost-to-benefit ratio for drug development changes as COPD evolves from one disease state into a larger disease spectrum. What is the current to future pipeline for drug R&D in the COPD arena, and is the horizon optimistic for delivering better treatment methods to patients? Joining Dr. Matt Birnholz to discuss the "Pulmonary Pipeline" is Dr. Nicholas Gross, pulmonologist and industry news reporter. Dr. Gross is emeritus professor of medicine and molecular biology at Loyola University in Chicago.
Updates from the "Pulmonary Pipeline" of COPD Drug Developments

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
In today's clinical practice, there is no appropriate "one size fits all" treatment approach for COPD. But while this progressive trend toward personalized medicine standards helps optimize COPD care for each patient, the cost-to-benefit ratio for drug development changes as COPD evolves from one disease state into a larger disease spectrum. What is the current to future pipeline for drug R&D in the COPD arena, and is the horizon optimistic for delivering better treatment methods to patients? Joining Dr. Matt Birnholz to discuss the "Pulmonary Pipeline" is Dr. Nicholas Gross, pulmonologist and industry news reporter. Dr. Gross is emeritus professor of medicine and molecular biology at Loyola University in Chicago.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Second-line Chemotherapy Options in Metastatic PDAC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?